New Injectable Agents for the Treatment of Type 2 Diabetes Part 2—Glucagon-Like Peptide-1 (GLP-1) AgonistsGLP-1 combination productsGlucagon like peptide-1 (GLP-1) agonistType 2 diabetesA comprehensive, collaborative approach is necessary for optimal treatment of patients with type 2 diabetes ...
Several new products and new formulations of existing products have recently been approved for the treatment of type 2 diabetes. They offer potential advantages such as lower risk of nocturnal hypoglycemia, fewer injections, and ease of dosing; however, they are expensive.References...
Tirzepatide is the first drug in a new class of diabetes medications. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.GLP-1andGIPare gut hormones called incretins, and the intestinesrelease themTrusted Sourcewhen we eat. Incretins stimulate the secretio...
Medications for diabetes comprise either GLP-1 receptor agonists, with short (one or two daily injections: Exenatide, Liraglutide, Lixisenatide) or long duration (one injection once weekly: extended-released Exenatide, Albiglutide, Dulaglutide, Taspoglutide); or oral compounds inhibiting dipeptidyl peptid...
Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication Economic impact of antidiabetic medications and glycemic control on managed care organizations: A review of the literature. J Manag Care Pharm. 2006;12(2... MD Dibonaventura,JS Wagner,...
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the
A new trial has discovered that individuals suffering from “blinding” headaches, known as Idiopathic Intracranial Hypertension (IIH), could potentially be treated with an injectable peptide typically used for type 2 diabetes. The study, published in the journalBrain, presents the results of a phas...
New connected device makes injectable insulin easier to monitor for diabetes type 1 patients Credit: INSULCLOCK The number of diabetics in the world, both insulin dependent and not insulin dependent, is 415 million and it is expected to grow to 600 million in 2040. If their treatment fails, ...
injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from the Phase 2 study in carcinoid syndrome will provide an ...
A single SGLT-2 inhibitor, dapagliflozin, has been available since 2014, and its use is increasing gradually, in part because of an additional effect on weight loss. Injectable medications to lower glucose include insulin and glucagon-like peptide-1 receptor analogues (GLP-1 RA). In public ...